PDS Biotechnology (PDSB) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PDS Biotechnology is the larger company by market cap ($100.0 million vs $99.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PDSB | PLYX |
|---|---|---|
| Share price | $1.38 | $2.00 |
| Market cap | $100.01M | $99.69M |
| 1-day change | +35.29% | 0.00% |
| YTD return | +79.22% | — |
| 1-year return | +39.96% | — |
| 5-year return | -88.81% | — |
| EPS (TTM) | $-0.64 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.55 | $48.91 |
| 52-week low | $0.195 | $1.85 |
| Distance from 52-week high | -10.97% | -95.91% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +262.32% | +275.00% |
| Average volume | 23.24M | 76.41K |
| Shares outstanding | 72.47M | 49.85M |
| Employees | 21 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PDSB vs PLYX FAQ
Which is bigger, PDS Biotechnology or Polaryx Therapeutics?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are PDS Biotechnology and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.